$24.67
-0.13-0.52%
Last update: Oct 30, 4:46 PM
Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History
VRDNNASDAQ
Roche earns FDA approval for Enspryng in thyroid eye disease, offering the only at-home subcutaneous treatment for TED.
You can purchase shares of Viridian Therapeutics (NASDAQ:VRDN) through any online brokerage.
Other companies in Viridian Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Viridian Therapeutics has a consensus price target of $37.40.
The stock price for Viridian Therapeutics (NASDAQ: VRDN) is $25.2 last updated October 30, 2026 at 4:46 PM EDT.
There are no upcoming dividends for Viridian Therapeutics.
Viridian Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Viridian Therapeutics.
Viridian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates,...
